U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H28N2O
Molecular Weight 288.4277
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUMECAINE

SMILES

CCCCN1CCCC1C(=O)NC2=C(C)C=C(C)C=C2C

InChI

InChIKey=VEPZOLKTNZOTTQ-UHFFFAOYSA-N
InChI=1S/C18H28N2O/c1-5-6-9-20-10-7-8-16(20)18(21)19-17-14(3)11-13(2)12-15(17)4/h11-12,16H,5-10H2,1-4H3,(H,19,21)

HIDE SMILES / InChI
Bumecaine (Pyromecaine) is a local anesthetic and anti-arrhythmic drug. It is indicated as an agent for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. The experiments on the isolated neurons in the rat spinal ganglions have shown that interaction of pyromecaine with inactivated Na+ channels makes a considerable contribution to the blocking effect of anesthesia. Oral administration of pyromecaine pills considerably depresses platelet aggregation and even causes platelet disaggregation. Possible side effects are: general weakness, nausea, vomiting, headache, dizziness, fainting, a drop in blood pressure. Quinidine increases the risk of side effects.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Bumecain

Approved Use

Pyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent.
Primary
Bumecain

Approved Use

Pyromecaine is prescribed as an anesthetic for superficial anesthesia during medical and diagnostic procedures in dentistry, ophthalmology, otorhinolaryngology, surgery, bronchology, gastroenterology, urology. Pyromecaine is also used as an antiarrhythmic agent.
PubMed

PubMed

TitleDatePubMed
[Effect of anti-angina therapy on phospholipid levels of the myocardium in ischemic lesions].
1988 Oct
Patents

Sample Use Guides

50-100 mg slowly. Prolonged therapy is given in a dose 100 mg 2-3 times with an interval between administrations of 15-20 minutes. The maximum dose is 1.5 g / day.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
BUMECAINE
INN  
INN  
Official Name English
BUMECAINE, (±)-
Common Name English
(±)-BUMECAINE
Common Name English
bumecaine [INN]
Common Name English
1-BUTYL-2',4',6'-TRIMETHYL-2-PYRROLIDINECARBOXANILIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C245
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL1870919
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
PUBCHEM
65770
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
NCI_THESAURUS
C72171
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
SMS_ID
100000088442
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
INN
2984
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
FDA UNII
B77K612SPZ
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
EVMPD
SUB05969MIG
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
CAS
30103-44-7
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID4046109
Created by admin on Fri Dec 15 16:21:16 GMT 2023 , Edited by admin on Fri Dec 15 16:21:16 GMT 2023
PRIMARY